Regulatory Roundup: John Taylor to Serve as Acting Principal Deputy Commissioner after Joshua Sharfstein's Departure, and more.

Article

John Taylor to Serve as Acting Principal Deputy Commissioner after Joshua Sharfstein's Departure, and more.

According to the FDA Press Office on Jan. 5, 2010, John Taylor, counselor to the commissioner, has been asked to serve as the acting principal deputycommissioner for the next 60 days. It was reported earlier this week that Joshua Sharfstein, principal deputy commissioner under Margaret Hamburg, wasleaving the agency to work for the state of Maryland as secretary of health. Dr. Hamburg issued a memo on the subject today.

The US Pharmacopeia (USP) released proposals for universal standards to guide the content, language, format, and appearance of prescription drug labels. USP is seeking comments from pharmacists and other healthcare professionals for the newly proposed General Chapter <17> Prescription Container Labeling. Comments are due Mar. 31, 2011. The development of the proposed standards was led by the Institute of Medicine (IOM) and aim to “improve health literacy in the United States by bringing together government, industry, associations, and other groups to advance practical strategies that can be implemented to maximize patient comprehension of health information,” according to the USP notice. The core components of the standard proposals include labeling prescriptions in a patient-centered manner; emphasizing instructions and other important information; giving explicit instructions, including the purpose for use; improving readability; and limiting auxiliary information.

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes